Key result
Glucose and fat metabolism are altered in pulmonary arterial hypertension, but it is not yet clear if these changes are causes or effects of the disease.
Highlights the association between systemic metabolic dysfunction (abnormal glucose and fat metabolism) and pulmonary arterial hypertension, noting the uncertainty of causality.
Pulmonary arterial hypertension (PAH) is characterised by progressive obliteration of the pulmonary vasculature, culminating in right-sided heart failure (HF). In recent years, studies have observed an association between systemic metabolic dysfunction, PAH and right ventricular failure [1]. Patients with PAH have an increased prevalence of obesity [2] and type 2 diabetes [3, 4]. Interestingly, abnormal glucose metabolism is evident even in non-diabetic individuals with PAH [5–7], and serves as an independent predictor of prognosis [8]. Glucose and fat metabolism are altered in pulmonary arterial hypertension, but it is not yet clear if these changes are causes or effects of the disease <http://bit.ly/3cWyf66>
No takes yet. Share an insight, caveat, or question.
Duan et al. (2020) conducted an editorial in Pulmonary arterial hypertension. Altered glucose and fat metabolism was evaluated. Glucose and fat metabolism are altered in pulmonary arterial hypertension, but it is not yet clear if these changes are causes or effects of the disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: